Table 2.
Association between APOL1 high–risk status and steady decline
| Model | APOL1 Low–Risk Group | APOL1 High–Risk Group |
|---|---|---|
| N | 485 | 137 |
| Steady decline, % | 20.0 | 40.0 |
| Unadjusted, OR (95% CI) | 1.00 | 2.45 (1.62 to 3.69) |
| Model 1, OR (95% CI) | 1.00 | 1.70 (1.08 to 2.68) |
| Model 2, OR (95% CI) | 1.00 | 1.59 (1.00 to 2.52) |
| Model 2 by subgroups, OR (95% CI) | ||
| eGFR<45 ml/min per 1.73 m2 | 1.00 | 2.12 (1.00 to 4.50) |
| eGFR≥45 ml/min per 1.73 m2 | 1.00 | 1.46 (0.76 to 2.78) |
| UPCR<220 mg/g | 1.00 | 1.40 (0.75 to 2.62) |
| UPCR≥220mg/g | 1.00 | 1.68 (0.80 to 3.53) |
Model 2 P for interaction between APOL1 risk status and eGFR stratified at 45 ml/min per 1.73 m2: 0.42. Model 2 P for interaction between APOL1 risk status and UPCR stratified at 0.22 g/g: 0.55. Model 1 covariates included age at randomization, sex, randomized drug treatment group, randomized BP target, baseline eGFR, log(proteinuria), and diastolic BP. Model 2 added follow-up time for trajectory estimate. OR, odds ratio; 95% CI, 95% confidence interval; UPCR, urine protein-to-creatinine ratio.